|
1
|
Bitton R: The economic burden of
osteoarthritis. Am J Manag Care. 15 Suppl 8:S230–S235.
2009.PubMed/NCBI
|
|
2
|
Ackerman IN, Pratt C, Gorelik A and Liew
D: Projected burden of osteoarthritis and rheumatoid arthritis in
Australia: A population-level analysis. Arthritis Care Res
(Hoboken). 2017.
|
|
3
|
Cicuttini FM and Wluka AE: Osteoarthritis:
Is OA a mechanical or systemic disease? Nat Rev Rheumatol.
10:515–516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Musumeci G, Szychlinska MA and Mobasheri
A: Age-related degeneration of articular cartilage in the
pathogenesis of osteoarthritis: Molecular markers of senescent
chondrocytes. Histol Histopathol. 30:1–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Srikanth VK, Fryer JL, Zhai G, Winzenberg
TM, Hosmer D and Jones G: A meta-analysis of sex differences
prevalence, incidence and severity of osteoarthritis.
Osteoarthritis Cartilage. 13:769–781. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Felson DT: An update on the pathogenesis
and epidemiology of osteoarthritis. Radiol Clin North Am. 42:1–9.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wei Y and Bai L: Recent advances in the
understanding of molecular mechanisms of cartilage degeneration,
synovitis and subchondral bone changes in osteoarthritis. Connect
Tissue Res. 57:245–261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
van der Kraan PM and van den Berg WB:
Chondrocyte hypertrophy and osteoarthritis: Role in initiation and
progression of cartilage degeneration? Osteoarthritis Cartilage.
20:223–232. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fosang AJ, Last K, Knauper V, Murphy G and
Neame PJ: Degradation of cartilage aggrecan by collagenase-3
(MMP-13). FEBS Lett. 380:17–20. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pufe T, Petersen W, Tillmann B and
Mentlein R: The splice variants VEGF121 and VEGF189 of the
angiogenic peptide vascular endothelial growth factor are expressed
in osteoarthritic cartilage. Arthritis Rheum. 44:1082–1088. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Enomoto H, Inoki I, Komiya K, Shiomi T,
Ikeda E, Obata K, Matsumoto H, Toyama Y and Okada Y: Vascular
endothelial growth factor isoforms and their receptors are
expressed in human osteoarthritic cartilage. Am J Pathol.
162:171–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pfander D, Körtje D, Zimmermann R, Weseloh
G, Kirsch T, Gesslein M, Cramer T and Swoboda B: Vascular
endothelial growth factor in articular cartilage of healthy and
osteoarthritic human knee joints. Ann Rheum Dis. 60:1070–1073.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pufe T, Harde V, Petersen W, Goldring MB,
Tillmann B and Mentlein R: Vascular endothelial growth factor
(VEGF) induces matrix metalloproteinase expression in immortalized
chondrocytes. J Pathol. 202:367–374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shen P, Jiao Z, Zheng JS, Xu WF, Zhang SY,
Qin A and Yang C: Injecting vascular endothelial growth factor into
the temporomandibular joint induces osteoarthritis in mice. Sci
Rep. 5:162442015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tibesku CO, Daniilidis K, Skwara A,
Paletta J, Szuwart T and Fuchs-Winkelmann S: Expression of vascular
endothelial growth factor on chondrocytes increases with
osteoarthritis-an animal experimental investigation. Open Orthop J.
5:177–180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yuan Q, Sun L, Li JJ and An CH: Elevated
VEGF levels contribute to the pathogenesis of osteoarthritis. BMC
Musculoskelet Disord. 15:4372014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagai T, Sato M, Kutsuna T, Kokubo M,
Ebihara G, Ohta N and Mochida J: Intravenous administration of
anti-vascular endothelial growth factor humanized monoclonal
antibody bevacizumab improves articular cartilage repair. Arthritis
Res Ther. 12:R1782010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Therapontos C, Erskine L, Gardner ER, Figg
WD and Vargesson N: Thalidomide induces limb defects by preventing
angiogenic outgrowth during early limb formation. Proc Natl Acad
Sci USA. 106:8573–8578. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D'Amato RJ, Loughnan MS, Flynn E and
Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl
Acad Sci USA. 91:4082–4085. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singhal S, Mehta J, Desikan R, Ayers D,
Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar
M, et al: Antitumor activity of thalidomide in refractory multiple
myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tan H, Chen H, Xu C, Ge Z, Gao Y, Fang J,
Liu W and Xiao S: Role of vascular endothelial growth factor in
angiodysplasia: An interventional study with thalidomide. J
Gastroenterol Hepatol. 27:1094–1101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mercurio A, Adriani G, Catalano A, Carocci
A, Rao L, Lentini G, Cavalluzzi MM, Franchini C, Vacca A and Corbo
F: A mini-review on thalidomide: Chemistry, mechanisms of action,
therapeutic potential and anti-angiogenic properties in multiple
myeloma. Curr Med Chem. 24:2736–2744. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Andersen NF, Vogel U, Klausen TW, Gimsing
P, Gregersen H, Abildgaard N and Vangsted AJ: Vascular endothelial
growth factor (VEGF) gene polymorphisms may influence the efficacy
of thalidomide in multiple myeloma. Int J Cancer. 131:E636–E642.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Behl T, Kaur I, Goel H and Kotwani A:
Significance of the antiangiogenic mechanisms of thalidomide in the
therapy of diabetic retinopathy. Vascul Pharmacol. 92:6–15. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Israyelyan A, Shannon EJ, Baghian A,
Kearney MT and Kousoulas KG: Thalidomide suppressed the growth of
4T1 cells into solid tumors in Balb/c mice in a combination therapy
with the oncolytic fusogenic HSV-1 OncdSyn. Cancer Chemother
Pharmacol. 64:1201–1210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lainer-Carr D and Brahn E: Angiogenesis
inhibition as a therapeutic approach for inflammatory synovitis.
Nat Clin Pract Rheumatol. 3:434–442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gordon JN and Goggin PM: Thalidomide and
its derivatives: Emerging from the wilderness. Postgrad Med J.
79:127–132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vasheghani F, Zhang Y, Li YH, Blati M,
Fahmi H, Lussier B, Roughley P, Lagares D, Endisha H, Saffar B, et
al: PPARγ deficiency results in severe, accelerated osteoarthritis
associated with aberrant mTOR signalling in the articular
cartilage. Ann Rheum Dis. 74:569–578. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kotoh T, Dhar DK, Masunaga R, Tabara H,
Tachibana M, Kubota H, Kohno H and Nagasue N: Antiangiogenic
therapy of human esophageal cancers with thalidomide in nude mice.
Surgery. 125:536–544. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu CY, Jiang XX, Zhu YH and Wei DN:
Metabotropic glutamate receptor 5 antagonist
2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects
in rats: Role of brain-derived neurotrophic factor. Neuroscience.
223:219–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Glasson SS, Chambers MG, Van Den Berg WB
and Little CB: The OARSI histopathology initiative-recommendations
for histological assessments of osteoarthritis in the mouse.
Osteoarthritis Cartilage. 18 Suppl 3:S17–S23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang MJ, Wang L, Jin DD, Zhang ZM, Chen
TY, Jia CH, Wang Y, Zhen XC, Huang B, Yan B, et al: Enhancement of
the synthesis of n-3 PUFAs in fat-1 transgenic mice inhibits mTORC1
signalling and delays surgically induced osteoarthritis in
comparison with wild-type mice. Ann Rheum Dis. 73:1719–1727. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jonason JH, Hoak D and O'Keefe RJ: Primary
murine growth plate and articular chondrocyte isolation and cell
culture. Methods Mol Biol. 1226:11–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Vargesson N: Thalidomide-induced
teratogenesis: History and mechanisms. Birth Defects Res C Embryo
Today. 105:140–156. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Alberto SF, Felix J and de Deus J:
Thalidomide for the treatment of severe intestinal bleeding.
Endoscopy. 40:788–789. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gu X, Zheng Y, Ren B, Zhang R, Mei F,
Zhang J and Ma Z: Intraperitoneal injection of thalidomide
attenuates bone cancer pain and decreases spinal tumor necrosis
factor-alpha expression in a mouse model. Mol Pain. 6:642010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Daruwalla J, Nikfarjam M,
Malcontenti-Wilson C, Muralidharan V and Christophi C: Effect of
thalidomide on colorectal cancer liver metastases in CBA mice. J
Surg Oncol. 91:134–140. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kenyon BM, Browne F and D'Amato RJ:
Effects of thalidomide and related metabolites in a mouse corneal
model of neovascularization. Exp Eye Res. 64:971–978. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xia B, Di Chen, Zhang J, Hu S, Jin H and
Tong P: Osteoarthritis pathogenesis: A review of molecular
mechanisms. Calcif Tissue Int. 95:495–505. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brinckerhoff CE and Matrisian LM: Matrix
metalloproteinases: A tail of a frog that became a prince. Nat Rev
Mol Cell Biol. 3:207–214. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Klein T and Bischoff R: Physiology and
pathophysiology of matrix metalloproteases. Amino Acids.
41:271–290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Tetlow LC, Adlam DJ and Woolley DE: Matrix
metalloproteinase and proinflammatory cytokine production by
chondrocytes of human osteoarthritic cartilage: Associations with
degenerative changes. Arthritis Rheum. 44:585–594. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Baragi VM, Becher G, Bendele AM, Biesinger
R, Bluhm H, Boer J, Deng H, Dodd R, Essers M, Feuerstein T, et al:
A new class of potent matrix metalloproteinase 13 inhibitors for
potential treatment of osteoarthritis: Evidence of histologic and
clinical efficacy without musculoskeletal toxicity in rat models.
Arthritis Rheum. 60:2008–2018. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hu Y, Xiang JS, DiGrandi MJ, Du X, Ipek M,
Laakso LM, Li J, Li W, Rush TS, Schmid J, et al: Potent, selective,
and orally bioavailable matrix metalloproteinase-13 inhibitors for
the treatment of osteoarthritis. Bioorg Med Chem. 13:6629–6644.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Janusz MJ, Bendele AM, Brown KK, Taiwo YO,
Hsieh L and Heitmeyer SA: Induction of osteoarthritis in the rat by
surgical tear of the meniscus: Inhibition of joint damage by a
matrix metalloproteinase inhibitor. Osteoarthritis Cartilage.
10:785–791. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Janusz MJ, Hookfin EB, Heitmeyer SA,
Woessner JF, Freemont AJ, Hoyland JA, Brown KK, Hsieh LC, Almstead
NG, De B, et al: Moderation of iodoacetate-induced experimental
osteoarthritis in rats by matrix metalloproteinase inhibitors.
Osteoarthritis Cartilage. 9:751–760. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ferrara N and Henzel WJ: Pituitary
follicular cells secrete a novel heparin-binding growth factor
specific for vascular endothelial cells. Biochem Biophys Res
Commun. 161:851–858. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kim KJ, Li B, Winer J, Armanini M, Gillett
N, Phillips HS and Ferrara N: Inhibition of vascular endothelial
growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature. 362:841–844. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Thysen S, Luyten FP and Lories RJ:
Targets, models and challenges in osteoarthritis research. Dis
Model Mech. 8:17–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Glyn-Jones S, Palmer AJ, Agricola R, Price
AJ, Vincent TL, Weinans H and Carr AJ: Osteoarthritis. Lancet.
386:376–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
